Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
See Latest ArticlesWeekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-operative Oncology Group
Oncology (Karger), 09/08/09
Papadimitriou CA et al. – Weekly administration of docetaxel and gemcitabine did not result in superior clinical outcomes over weekly docetaxel.
Methods- Randomized phase II trial
- Second-line chemotherapy in patients with metastatic breast cancer who have failed a pacclitaxel-containing regimen
- Randomization to receive docetaxel (40 mg/m2; group 1, n=34) or docetaxel (35 mg/m2) with gemcitabine (600 mg/m2; group 2, n=41)
- 3 weekly infusions with a 1-week rest period
- ORR was 18% and 27.5% in groups 1 and 2, respectively
- No difference in median OS and TTP
- Grades 3 and 4 neutropenia were higher in group 2 (23% vs. 3%)
Related Articles
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer Trial
Journal of Clinical Oncology, 11/05/09
Relevance Score: 93%
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
Annals of Oncology, 10/13/09
Relevance Score: 93%
Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer
Annals of Oncology, 11/16/09
Relevance Score: 91%
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Annals of Oncology, 10/30/09
Relevance Score: 89%
Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status
Anti-Cancer Drugs, 10/16/09
Relevance Score: 88%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Optimizing conventional therapies for inflammatory bowel disease
Current Gastroenterology Reports, 12/07/09
Linezolid in the Treatment of Multidrug-Resistant Tuberculosis
Clinical Infectious Diseases, 12/07/09
Review: erythropoiesis-stimulating agents increase mortality in patients with cancer
Evidence-Based Medicine, 12/07/09
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Review: erythropoiesis-stimulating agents increase mortality in patients with cancer
Evidence-Based Medicine, 12/07/09
Blood pressure and risk of prostate cancer: Cohort Norway (CONOR)
Cancer Causes and Control, 12/07/09
Pancreatic Endoscopic Ultrasound-guided Fine Needle Aspiration: Complication rate and clinical course in a single centre
Digestive and Liver Diseases, 12/07/09
Today in Women`s Health...keeping you current
Receive free subspecialty "5-minute updates" via email
Yoga in Female Sexual Functions
The Journal of Sexual Medicine, 12/07/09
Coronary heart disease and menopause management: The swinging pendulum of HRT
Atherosclerosis, 12/04/09
Vitamin K2 supplementation does not influence bone loss in early menopausal women: A randomised double-blind placebo-controlled trial
Osteoporosis International, 12/03/09
Sponsor
Article Search
Sponsor
Sponsor